carbamates has been researched along with Drug Refractory Epilepsy in 12 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to evaluate the efficacy and safety of adjunctive retigabine/ezogabine (RTG/EZG) therapy in Asian adults with partial-onset seizures." | 9.22 | Efficacy and safety of retigabine/ezogabine as adjunctive therapy in adult Asian patients with drug-resistant partial-onset seizures: A randomized, placebo-controlled Phase III study. ( Kwan, P; Lim, KS; Lotay, N; White, R, 2016) |
| "Diazepam-resistant SE was induced in adult mice fed with standard or ketogenic diet or in cannabinoid receptor type 1 (CB1) receptor knock-out mice." | 5.48 | Inhibition of monoacylglycerol lipase terminates diazepam-resistant status epilepticus in mice and its effects are potentiated by a ketogenic diet. ( Butler, CR; Guilmette, E; Pauletti, A; Piro, JR; Porcu, L; Rizzi, M; Salamone, A; Samad, TA; Sheehan, MJ; Terrone, G; Vezzani, A; Villa, BR, 2018) |
| "The purpose of this study was to evaluate the efficacy and safety of adjunctive retigabine/ezogabine (RTG/EZG) therapy in Asian adults with partial-onset seizures." | 5.22 | Efficacy and safety of retigabine/ezogabine as adjunctive therapy in adult Asian patients with drug-resistant partial-onset seizures: A randomized, placebo-controlled Phase III study. ( Kwan, P; Lim, KS; Lotay, N; White, R, 2016) |
| "Management of drug resistant epilepsy (DRE) represents a challenge to the treating clinician." | 3.01 | Cenobamate in refractory epilepsy: Overview of treatment options and practical considerations. ( Ben-Menachem, E; Kälviäinen, R; Lattanzi, S; Nashef, L; Schmitz, B; Vonck, K, 2023) |
| " We calculated the risk ratio (RR) of ≥50%, ≥75% and 100% reduction in seizure frequency from baseline, as well as dropout and serious adverse events related to treatment." | 2.72 | Efficacy and safety of cenobamate in patients with uncontrolled focal seizures: A meta-analysis. ( Wang, C; Wang, J; Zhang, L, 2021) |
| "We measured seizure reduction, median reduction in seizure frequency, median dose, responder rate, and treatment-emergent adverse events." | 1.72 | Adjunctive use of cenobamate for pediatric refractory focal-onset epilepsy: A single-center retrospective study. ( Karkare, S; Kothare, SV; Shah, YD; Varughese, RT, 2022) |
| "Diazepam-resistant SE was induced in adult mice fed with standard or ketogenic diet or in cannabinoid receptor type 1 (CB1) receptor knock-out mice." | 1.48 | Inhibition of monoacylglycerol lipase terminates diazepam-resistant status epilepticus in mice and its effects are potentiated by a ketogenic diet. ( Butler, CR; Guilmette, E; Pauletti, A; Piro, JR; Porcu, L; Rizzi, M; Salamone, A; Samad, TA; Sheehan, MJ; Terrone, G; Vezzani, A; Villa, BR, 2018) |
| "Retigabine reduced seizure frequency or severity for 24." | 1.43 | Adjunctive retigabine in refractory focal epilepsy: Postmarketing experience at four tertiary epilepsy care centers in Germany. ( Elger, CE; Graf, W; Hamer, HM; Kasper, B; Kull, A; Kurth, C; Nass, RD; Rosenow, F; Steinhoff, BJ; Strzelczyk, A; Surges, R, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 7 (58.33) | 2.80 |
| Authors | Studies |
|---|---|
| Lu, C | 1 |
| Zheng, J | 1 |
| Cao, Y | 1 |
| Bresnahan, R | 1 |
| Martin-McGill, KJ | 1 |
| Varughese, RT | 1 |
| Shah, YD | 1 |
| Karkare, S | 1 |
| Kothare, SV | 1 |
| Rissardo, JP | 1 |
| Fornari Caprara, AL | 1 |
| Makridis, KL | 1 |
| Kaindl, AM | 1 |
| Schmitz, B | 1 |
| Lattanzi, S | 1 |
| Vonck, K | 1 |
| Kälviäinen, R | 1 |
| Nashef, L | 1 |
| Ben-Menachem, E | 1 |
| Wheless, JW | 1 |
| Zhang, L | 1 |
| Wang, J | 1 |
| Wang, C | 1 |
| Terrone, G | 1 |
| Pauletti, A | 1 |
| Salamone, A | 1 |
| Rizzi, M | 1 |
| Villa, BR | 1 |
| Porcu, L | 1 |
| Sheehan, MJ | 1 |
| Guilmette, E | 1 |
| Butler, CR | 1 |
| Piro, JR | 1 |
| Samad, TA | 1 |
| Vezzani, A | 1 |
| Vanhoof-Villalba, SL | 1 |
| Gautier, NM | 1 |
| Mishra, V | 1 |
| Glasscock, E | 1 |
| Brodie, MJ | 1 |
| Nass, RD | 1 |
| Kurth, C | 1 |
| Kull, A | 1 |
| Graf, W | 1 |
| Kasper, B | 1 |
| Hamer, HM | 1 |
| Strzelczyk, A | 1 |
| Elger, CE | 1 |
| Steinhoff, BJ | 1 |
| Surges, R | 1 |
| Rosenow, F | 1 |
| Lim, KS | 1 |
| Lotay, N | 1 |
| White, R | 1 |
| Kwan, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset Seizures.[NCT00740623] | Phase 3 | 547 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| [NCT00228969] | Phase 2 | 0 participants | Interventional | 2005-02-28 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects With Partial Onset Seizures Followed by an Open-Label Extension Study.[NCT00425282] | Phase 3 | 566 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Epilepsy Phase III Trial[NCT00433667] | Phase 3 | 563 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Clinical Validation Study of the Simplified Seizure Classification Algorithm[NCT03796520] | 240 participants (Actual) | Observational | 2019-06-02 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for carbamates and Drug Refractory Epilepsy
| Article | Year |
|---|---|
Carisbamate add-on therapy for drug-resistant focal epilepsy.
Topics: Adult; Anticonvulsants; Carbamates; Drug Resistant Epilepsy; Drug Therapy, Combination; Epilepsies, | 2021 |
Carisbamate add-on therapy for drug-resistant focal epilepsy.
Topics: Adult; Anticonvulsants; Carbamates; Drug Resistant Epilepsy; Drug Therapy, Combination; Epilepsies, | 2021 |
Carisbamate add-on therapy for drug-resistant focal epilepsy.
Topics: Adult; Anticonvulsants; Carbamates; Drug Resistant Epilepsy; Drug Therapy, Combination; Epilepsies, | 2021 |
Carisbamate add-on therapy for drug-resistant focal epilepsy.
Topics: Adult; Anticonvulsants; Carbamates; Drug Resistant Epilepsy; Drug Therapy, Combination; Epilepsies, | 2021 |
Carisbamate add-on therapy for drug-resistant focal epilepsy.
Topics: Adult; Anticonvulsants; Carbamates; Drug Resistant Epilepsy; Drug Therapy, Combination; Epilepsies, | 2021 |
Carisbamate add-on therapy for drug-resistant focal epilepsy.
Topics: Adult; Anticonvulsants; Carbamates; Drug Resistant Epilepsy; Drug Therapy, Combination; Epilepsies, | 2021 |
Carisbamate add-on therapy for drug-resistant focal epilepsy.
Topics: Adult; Anticonvulsants; Carbamates; Drug Resistant Epilepsy; Drug Therapy, Combination; Epilepsies, | 2021 |
Carisbamate add-on therapy for drug-resistant focal epilepsy.
Topics: Adult; Anticonvulsants; Carbamates; Drug Resistant Epilepsy; Drug Therapy, Combination; Epilepsies, | 2021 |
Carisbamate add-on therapy for drug-resistant focal epilepsy.
Topics: Adult; Anticonvulsants; Carbamates; Drug Resistant Epilepsy; Drug Therapy, Combination; Epilepsies, | 2021 |
Carisbamate add-on therapy for drug-resistant focal epilepsy.
Topics: Adult; Anticonvulsants; Carbamates; Drug Resistant Epilepsy; Drug Therapy, Combination; Epilepsies, | 2021 |
Carisbamate add-on therapy for drug-resistant focal epilepsy.
Topics: Adult; Anticonvulsants; Carbamates; Drug Resistant Epilepsy; Drug Therapy, Combination; Epilepsies, | 2021 |
Carisbamate add-on therapy for drug-resistant focal epilepsy.
Topics: Adult; Anticonvulsants; Carbamates; Drug Resistant Epilepsy; Drug Therapy, Combination; Epilepsies, | 2021 |
Carisbamate add-on therapy for drug-resistant focal epilepsy.
Topics: Adult; Anticonvulsants; Carbamates; Drug Resistant Epilepsy; Drug Therapy, Combination; Epilepsies, | 2021 |
Carisbamate add-on therapy for drug-resistant focal epilepsy.
Topics: Adult; Anticonvulsants; Carbamates; Drug Resistant Epilepsy; Drug Therapy, Combination; Epilepsies, | 2021 |
Carisbamate add-on therapy for drug-resistant focal epilepsy.
Topics: Adult; Anticonvulsants; Carbamates; Drug Resistant Epilepsy; Drug Therapy, Combination; Epilepsies, | 2021 |
Carisbamate add-on therapy for drug-resistant focal epilepsy.
Topics: Adult; Anticonvulsants; Carbamates; Drug Resistant Epilepsy; Drug Therapy, Combination; Epilepsies, | 2021 |
Cenobamate (YKP3089) and Drug-Resistant Epilepsy: A Review of the Literature.
Topics: Animals; Carbamates; Chlorophenols; Drug Resistant Epilepsy; Seizures; Tetrazoles; United States | 2023 |
Real-world experience with cenobamate: A systematic review and meta-analysis.
Topics: Adult; Anticonvulsants; Carbamates; Child; Drug Resistant Epilepsy; Epilepsies, Partial; Humans; Sei | 2023 |
Cenobamate in refractory epilepsy: Overview of treatment options and practical considerations.
Topics: Anticonvulsants; Carbamates; Drug Resistant Epilepsy; Epilepsies, Partial; Humans; Tetrazoles | 2023 |
Adjunctive cenobamate for the treatment of focal onset seizures in adults with epilepsy: a critical review.
Topics: Adult; Animals; Anticonvulsants; Carbamates; Chlorophenols; Drug Resistant Epilepsy; Humans; Tetrazo | 2020 |
Efficacy and safety of cenobamate in patients with uncontrolled focal seizures: A meta-analysis.
Topics: Anticonvulsants; Carbamates; Chlorophenols; Dizziness; Dose-Response Relationship, Drug; Drug Resist | 2021 |
Practical Use of Newer Antiepileptic Drugs as Adjunctive Therapy in Focal Epilepsy.
Topics: Acetamides; Adult; Aged; Animals; Anticonvulsants; Carbamates; Dibenzazepines; Drug Resistant Epilep | 2015 |
1 trial available for carbamates and Drug Refractory Epilepsy
| Article | Year |
|---|---|
Efficacy and safety of retigabine/ezogabine as adjunctive therapy in adult Asian patients with drug-resistant partial-onset seizures: A randomized, placebo-controlled Phase III study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamates; Double-Blind Method; Drug Resistant Epilepsy; | 2016 |
4 other studies available for carbamates and Drug Refractory Epilepsy
| Article | Year |
|---|---|
Adjunctive use of cenobamate for pediatric refractory focal-onset epilepsy: A single-center retrospective study.
Topics: Adolescent; Adult; Anticonvulsants; Carbamates; Child; Chlorophenols; Drug Resistant Epilepsy; Epile | 2022 |
Inhibition of monoacylglycerol lipase terminates diazepam-resistant status epilepticus in mice and its effects are potentiated by a ketogenic diet.
Topics: Animals; Brain; Brain Waves; Carbamates; Cognition Disorders; Diazepam; Disease Models, Animal; Dose | 2018 |
Pharmacogenetics of KCNQ channel activation in 2 potassium channelopathy mouse models of epilepsy.
Topics: Animals; Anticonvulsants; Atrioventricular Block; Behavior, Animal; Bradycardia; Carbamates; Channel | 2018 |
Adjunctive retigabine in refractory focal epilepsy: Postmarketing experience at four tertiary epilepsy care centers in Germany.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamates; Child; Death, Sudden, Cardiac; Drug Resistant | 2016 |